Results 41 to 50 of about 4,984,276 (289)

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]

, 2019
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Annunziata, M., Casale, B., Cerchione, C., Crisa, E., Giordano, C., Grimaldi, F., Iovine, M., Luciano, L., Martinelli, V., Nappi, D., Pane, F., Pezzullo, L., Picardi, M., Pugliese, N., Villa, M. R.   +14 more
core   +1 more source

Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor

Revista Brasileira de Hematologia e Hemoterapia, 2014
Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow ...
Cesar Cilento Ponce, Maria de Lourdes Lopes Ferrari Chauffaille, Silvia Saiuli Miki Ihara, Maria Regina Regis Silva   +3 more
doaj   +1 more source

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core   +2 more sources

Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice

Leukemia, 2020
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by clonal myeloproliferation, progressive bone marrow (BM) fibrosis, splenomegaly, and anemia.
Yoshinori Ozono, K. Shide, T. Kameda, Ayako Kamiunten, Yuki Tahira, M. Sekine, Keiichi Akizuki, Kenichi Nakamura, Hisayoshi Iwakiri, Mitsue Sueta, T. Hidaka, Y. Kubuki, Shojiro Yamamoto, S. Hasuike, A. Sawaguchi, K. Nagata, K. Shimoda   +16 more
semanticscholar   +1 more source

Targeted sequencing of candidate gene regions for myelofibrosis in dogs

Journal of Veterinary Internal Medicine, 2022
Background Myelofibrosis often lacks an identifiable cause in dogs. In humans, most primary myelofibrosis cases develop secondary to driver mutations in JAK2, CALR, or MPL.
Amelia G. Campbell, Davis M. Seelig, Joan D. Beckman, Katie M. Minor, Daniel A. Heinrich, Steven G. Friedenberg, Jaime F. Modiano, Eva Furrow   +7 more
doaj   +1 more source

The degree of anisocytosis predicts survival in patients with primary myelofibrosis [PDF]

, 2016
Introduction: Red cell distribution width (RDW) provides a quantitative measure of anisocytosis and it is associated with the presence of subclinical systemic inflammation and a poor outcome in a variety of diseases when elevated.
Hariš, Višnja, Jakšić, Ozren, Kušec, Rajko, Lucijanić, Marko, Mitrović, Zdravko, Pejša, Vlatko, Piršić, Mario, Prka, Željko, Tomasović-Lončarić, Čedna, Vasilj, Tamara, Štoos-Veić, Tajana   +10 more
core   +1 more source

Lysyl oxidase inhibition in primary myelofibrosis: A renewed strategy

Archives of Stem Cell and Therapy, 2020
Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) that portends a poor prognosis and has limited options for treatment. PMF is often driven by clonal mutations in one of three genes that regulate the JAK-STAT signaling pathway ...
Andrew J. Piasecki, O. Leiva, K. Ravid
semanticscholar   +1 more source

Treatment of primary myelofibrosis

Turkish Journal of Hematology, 2009
Şinasi Özsoylu
doaj   +2 more sources

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]

, 2020
Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M, Fleischman, Angela G, Huynh, Christy, Morse, Sarah J, Nguyen, Hellen, Nguyen, Jenny, Nguyen, Thanh Kim   +6 more
core  

Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease [PDF]

, 2016
Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable ...
How, Joan, Oh, Stephen T, Zhou, Amy
core   +2 more sources